Here’s what you should know:
1. The company is in the process of validating two clinical trials, in an attempt to earn a CE Mark.
2. If successful, the company plans to launch a frontline CRC screening product sometime in 2018.
3. Volition’s CEO Cameron Reynolds said in a release the product launch will be the company’s “largest near-term opportunity.” He added the European market has 150 million-plus residents of screening age.
4. Volition is in the midst of a U.S.-based study as well. The company is conducting a 13,500 patient study with the Early Detection Research Network and Rockville, Md.-based U.S. National Cancer Institute.
More articles on gastroenterology:
GI leader to know: Dr. Francis Farraye of Boston Medical Center
Stock market week-in-review for 5 large GI companies — Sept. 11-15
Patient engagement, case conference less effective in IBD care than perceived
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.